Maitake (Expanded) for Blood Pressure Regulation

Research suggests that Maitake mushroom and its isolated fractions may have blood pressure-lowering properties, with the available evidence drawing from a consistent body of animal studies spanning several decades. Studies indicate that whole Maitake powder, the SX fraction, and bioactive peptides derived from Grifola frondosa have each demonstrated reductions in systolic and, in some cases, diastolic blood pressure across multiple rodent models, including spontaneously hypertensive rats, insulin-resistant Zucker fatty rats, and aging diabetic rats, with proposed mechanisms involving inhibition of the renin-angiotensin system, modulation of nitric oxide pathways, and ACE inhibition. Two reviews from 2001 and 2009 also note hypertension as among the conditions for which Maitake extracts have been studied. The primary limitation of this body of evidence is that it consists almost entirely of preclinical animal research, with no randomized controlled trials or robust human clinical data identified, meaning the extent to which these findings translate to humans remains an open question.